Search results for "Drug Design"

showing 10 items of 232 documents

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

Synthesis and antiproliferative mechanism of action of pyrrolo[3′,2′:6,7] cyclohepta[1,2-d]pyrimidin-2-amines as singlet oxygen photosensitizers

2016

A new series of pyrrolo[3′,2′:6,7]cyclohepta[1,2-d]pyrimidin-2-amines, was conveniently prepared using a versatile and high yielding multistep sequence. A good number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against three different human tumor cell lines with EC50 (0.08–4.96 μM) values reaching the nanomolar level. Selected compounds were investigated by laser flash photolysis. The most photocytotoxic derivative, exhibiting a fairly long-lived triplet state (τ ∼ 7 μs) and absorbance in the UV–Vis, was tested in the photo-oxidations of 9,10-anthracenedipropionic acid (ADPA) by singlet oxygen. The photosentizing properties are responsible for the c…

0301 basic medicinemedicine.medical_treatmentPhotodynamic therapyChemistry Techniques SyntheticAntiproliferative activityPhotochemistry01 natural sciencesPhotodynamic therapychemistry.chemical_compound7]cyclohepta[1Drug DiscoveryTriplet stateAmineschemistry.chemical_classificationPhotosensitizing AgentsCell DeathSinglet OxygenChemistrySinglet oxygenGeneral MedicineAntiproliferative activity; Photodynamic therapy; Photosensitizing agents; Pyrrolo[3′; 2′:6; 7]cyclohepta[1; 2-d]pyrimidin-2-amines; Reactive oxygen species; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyPyrrolo[3′2′:67]cyclohepta[12-d]pyrimidin-2-amineSettore ING-IND/22 - Scienza E Tecnologia Dei Materiali2-d]pyrimidin-2-aminesFlash photolysisReactive oxygen specieKineticsAntineoplastic AgentsAbsorbance03 medical and health sciencesCell Line TumormedicineHumansPyrrolo[3′Cell ProliferationPharmacologyReactive oxygen speciesPhotosensitizing agentPhotolysis010405 organic chemistry2′:6Drug Discovery3003 Pharmaceutical SciencePhotodissociationOrganic ChemistryCombinatorial chemistrySettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesAntiproliferative activity; Photodynamic therapy; Photosensitizing agents; Pyrrolo[3′2′:67]cyclohepta[12-d]pyrimidin-2-amines; Reactive oxygen species; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyKinetics030104 developmental biologyDrug DesignReactive oxygen species
researchProduct

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

2021

The approval of the first HIV-1 protease inhibitors (HIV-1 PRIs) marked a fundamental step in the control of AIDS, and this class of agents still represents the mainstay therapy for this illness. Despite the undisputed benefits, the necessary lifelong treatment led to numerous severe side-effects (metabolic syndrome, hepatotoxicity, diabetes, etc.). The HIV-1 PRIs are capable of interacting with “secondary” targets (off-targets) characterized by different biological activities from that of HIV-1 protease. In this scenario, the in-silico techniques undoubtedly contributed to the design of new small molecules with well-fitting selectivity against the main target, analyzing possible undesirabl…

0301 basic medicineon/off-targetsProtein ConformationComputer sciencemedicine.medical_treatmentHIV InfectionsLigands01 natural sciencesHIV ProteaseHIV-1 proteaseCatalytic DomainDrug DiscoveryBiology (General)DRUDITSpectroscopyMolecular StructurebiologyGeneral MedicineResearch processSmall moleculeComputer Science ApplicationsMolecular Docking SimulationChemistryligand-structure basedQH301-705.5NCI databaseComputational biologyArticleCatalysisInorganic ChemistryStructure-Activity Relationshipmolecular descriptors03 medical and health sciencesHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical ChemistryQD1-999Molecular BiologyVirtual screeningProteaseOrganic ChemistryHIV Protease Inhibitorsmolecular dockingvirtual screening0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyDrug DesignHIV-1biology.proteinInternational Journal of Molecular Sciences
researchProduct

Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases.

2015

Background and Aims: The clinical use of azathioprine and 6-mercaptopurine is limited by their delayed onset of action and potential side effects such as myelosuppression and hepatotoxicity. As these drugs specifically target the Vav1/Rac1 signalling pathway in T lamina propria lymphocytes via their metabolite 6-thio-GTP, we studied expression and optimised suppression of this pathway in inflammatory bowel diseases [IBD]. Methods: Rac1 and Vav1 expressions were analysed in mucosal immune cells in IBD patients. Targeted molecular modelling of the 6-thio-GTP molecule was performed to optimise Rac1 blockade; 44 modified designer thiopurine-analogues were tested for apoptosis induction, potenti…

0301 basic medicinerac1 GTP-Binding Proteinmedicine.medical_treatmentT-LymphocytesAzathioprineApoptosisInflammatory bowel diseaseDesigner Drugs03 medical and health sciences0302 clinical medicineImmune systemIntestinal mucosamedicineHumansIntestinal MucosaProto-Oncogene Proteins c-vavLamina propriaThiopurine methyltransferasebiologybusiness.industryMercaptopurineGastroenterologyImmunosuppressionGeneral Medicinemedicine.diseaseInflammatory Bowel Diseases030104 developmental biologymedicine.anatomical_structureApoptosisCase-Control StudiesDrug DesignImmunologybiology.protein030211 gastroenterology & hepatologybusinessBiomarkersImmunosuppressive Agentsmedicine.drugSignal TransductionJournal of Crohn'scolitis
researchProduct

Synchronizing the release rates of salicylate and indomethacin from degradable chitosan hydrogel and its optimization by definitive screening design.

2018

Abstract Three types of ionically crosslinked (with citric acid) chitosan discs were loaded with the highly water- soluble drug, sodium salicylate (SS) and the poorly water-soluble drug, indomethacin (Ind). In separate experiments the hydrated discs were immersed in a de-crosslinking solution comprising of different concentrations of calcium chloride, which induced a controlled erosion of the discs, a process which was optimized to synchronize the release rates of the two drugs over a predetermined period of time. The optimization was accomplished by manipulating six factors: chitosan MW, its amount in the formulation, the concentration of the crosslinker agent, the concentration of the de-…

3003DrugSynchronized release ratemedia_common.quotation_subjectIndomethacinPharmaceutical Sciencechemistry.chemical_elementmacromolecular substances02 engineering and technologyCalciumTriggered erosionCitric AcidChitosan03 medical and health scienceschemistry.chemical_compoundCrosslinked chitosan0302 clinical medicineDrug Delivery SystemsScreening designMultifactorial definitive screening designDissolutionSodium salicylatemedia_commonChitosanChromatographytechnology industry and agricultureHydrogelsCrosslinked chitosanDual drug platform021001 nanoscience & nanotechnologyDrug LiberationCross-Linking Reagentschemistry030220 oncology & carcinogenesisDrug Design0210 nano-technologyCitric acidSalicylic AcidEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

2021

Adenosine-triphosphate-(ATP)-binding cassette (ABC) transport proteins are ubiquitously present membrane-bound efflux pumps that distribute endo- and xenobiotics across intra- and intercellular barriers. Discovered over 40 years ago, ABC transporters have been identified as key players in various human diseases, such as multidrug-resistant cancer and atherosclerosis, but also neurodegenerative diseases, such as Alzheimer���s disease (AD). Most prominent and well-studied are ABCB1, ABCC1, and ABCG2, not only due to their contribution to the multidrug resistance (MDR) phenotype in cancer, but also due to their contribution to AD. However, our understanding of other ABC transporters is limited…

ABCG2 (BCRP)Multitarget inhibitor (PANABC)Broad-spectrum modulatorPolypharmacologyActivationNeurosciences. Biological psychiatry. NeuropsychiatryAmyloid-beta (Aβ / Abeta)ABCA2ABCA5ArticleABCA7InductionABCB1 (P-gp)Pattern analysisDownregulationPET Tracer (PETABC)ABC transporterABCA1 (ABC1)Rational drug design and developmentAlzheimer’s diseaseRC321-571ABCC1 (MRP1)InhibitionFree neuropathology
researchProduct

Binding mode analysis of ABCA7 for the prediction of novel Alzheimer's disease therapeutics

2021

Graphical abstract

ATP Adenosine-triphosphateNBD nucleotide binding domainGSH reduced glutathionePolypharmacologyAlzheimer’s disease (AD)ATP-binding cassette transporterHTS high-throughput screeningBiochemistryABCA7Structural BiologyPLIF protein ligand interactionMSD membrane spanning domainPDB protein data bankTM transmembrane helixABC ATP-binding cassetteMultitarget modulation (PANABC)RMSD root mean square distanceABC transporter (ABCA1 ABCA4 ABCA7)Computer Science ApplicationsMOE Molecular Operating EnvironmentPharmacophoreSNP single-nucleotide polymorphismBiotechnologyResearch ArticleBBB blood-brain barrierBiophysicsDrug designComputational biologyBiologyAD Alzheimer’s diseasePET positron emission tomographyIC intracellular helixAPP amyloid precursor proteincryo-EM cryogenic-electron microscopyGeneticsHomology modelingBinding siteRational drug design and developmentComputingMethodologies_COMPUTERGRAPHICSNBD-cholesterol 7-nitro-2-13-benzoxadiazol-4-yl-cholesterolTransporterPSO particle swarm optimizationPET tracer (PETABC)ECD extracellular domainR-domain/region regulatory domain/regionABCA1biology.proteinEH extracellular helixTP248.13-248.65BODIPY-cholesterol 44-difluoro-4-bora-3a4a-diaza-s-indacene-cholesterolComputational and Structural Biotechnology Journal
researchProduct

Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transpo…

2021

Orally dosed drugs must dissolve in the gastrointestinal (GI) tract before being absorbed through the epithelial cell membrane. In vivo drug dissolution depends on the GI tract's physiological conditions such as pH, residence time, luminal buffers, intestinal motility, and transit and drug properties under fed and fasting conditions (Paixao, P. et al. Mol. Pharm. 2018 and Bermejo, et al. M. Mol. Pharm. 2018). The dissolution of an ionizable drug may benefit from manipulating in vivo variables such as the environmental pH using pH-modifying agents incorporated into the dosage form. A successful example is the use of such agents for dissolution enhancement of BCS class IIb (high-permeability,…

Absorption (pharmacology)Chemistry PharmaceuticalAdministration OralBiological AvailabilityPharmaceutical ScienceModels BiologicalDosage formAcid dissociation constantExcipientsFumaratesDrug DiscoveryHumansComputer SimulationDissolution testingSolubilityTartratesDissolutionChromatographyChemistryHydrogen-Ion ConcentrationStomach emptyingBetaineDrug LiberationSolubilityGastrointestinal AbsorptionDrug DesignMolecular MedicineWeak baseMolecular Pharmaceutics
researchProduct

Estimation of ADME Properties in Drug Discovery: Predicting Caco-2 Cell Permeability Using Atom-Based Stochastic and Non-stochastic Linear Indices

2007

The in vitro determination of the permeability through cultured Caco-2 cells is the most often-used in vitro model for drug absorption. In this report, we use the largest data set of measured P(Caco-2), consisting of 157 structurally diverse compounds. Linear discriminant analysis (LDA) was used to obtain quantitative models that discriminate higher absorption compounds from those with moderate-poorer absorption. The best LDA model has an accuracy of 90.58% and 84.21% for training and test set. The percentage of good correlation, in the virtual screening of 241 drugs with the reported values of the percentage of human intestinal absorption (HIA), was greater than 81%. In addition, multiple …

Absorption (pharmacology)Stochastic ProcessesVirtual screeningQuantitative structure–activity relationshipDrug discoveryStereochemistryLinear modelQuantitative Structure-Activity RelationshipPharmaceutical ScienceLinear discriminant analysisPermeabilityData setROC CurveDrug DesignTest setLinear regressionLinear ModelsHumansPharmacokineticsCaco-2 CellsBiological systemADMEMathematicsJournal of Pharmaceutical Sciences
researchProduct

Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.

2005

: Background: Cyclic GMP (cGMP) concentration is increased in plasma of patients with liver cirrhosis. Three possible mechanisms may contribute: increased cGMP synthesis by soluble (activated by nitric oxide), or particulate (activated by atrial natriuretic peptide (ANP)) guanylate cyclase or increased release from cells. Aim: The aim of this work was to analyze the possible contributors to increased plasma cGMP and to assess whether changes in the parameters of the system vary with the degree of liver disease (Child Pugh score) or by the presence of ascites. Methods: We measured cGMP in plasma and lymphocytes, soluble guanylate cyclase activation by nitric oxide in lymphocytes, nitrates an…

AdultLiver CirrhosisMalemedicine.medical_specialtyGUCY1B3Nitric OxideNitric oxidechemistry.chemical_compoundAtrial natriuretic peptideInternal medicinemedicineHumansLymphocytesCyclic GMPCells CulturedNitritesAgedNitratesHepatologyPenicillamineGUCY1A3AscitesMiddle AgedNPR1PDE5 drug designEndocrinologychemistryGuanylate CyclaseCGMP transportAtrial Natriuretic FactorHomeostasisLiver International
researchProduct